We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Cochlear Implantation for Treatment of Single-sided Deafness

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02532972
Recruitment Status : Terminated (Closed by IRB)
First Posted : August 26, 2015
Results First Posted : March 11, 2020
Last Update Posted : May 5, 2020
University of Wisconsin, Madison
Information provided by (Responsible Party):
Dr. Daniel Lee, Massachusetts Eye and Ear Infirmary

Brief Summary:
This is a research study to determine whether a cochlear implantation (CI) device can improve hearing in people who are deaf in one ear (known as single-sided deafness).

Condition or disease Intervention/treatment Phase
Total Unilateral Deafness Unilateral Partial Deafness Device: Med-el MAESTRO Cochlear Implant with Flex 28 electrode array Not Applicable

Detailed Description:
The goal of this study is to further investigate the role of CI in treating unilateral hearing loss and associated tinnitus. Single-sided deafness (SSD) afflicts approximately 60,000 new patients per year in the United States. The most common causes of these single-sided losses are sudden sensorineural hearing loss, Meniere's disease, trauma, and vestibular schwannoma. Patients with SSD face significant difficulty with communicating in the presence of background noise and in sound localization. Another significant problem for some SSD patients is tinnitus, which can be incapacitating and for which there are no therapies available that are considered to be of sufficient reliability to become a standard of care. Difficulty hearing in background noise and increased tinnitus can lead to significant frustration in social situations and contribute to increased isolation and a decreased quality of life. Treatment options for single sided deafness in the United States include contralateral routing of signals (CROS) hearing aids, bone-anchored hearing aids (BAHA) and use of assistive devices to improve the signal-to-noise in group situations. The first two devices take sound from the affected ear and transmit it to the unaffected ear. The last device consists of having a speaker wear a microphone and routing the signal directly to the patient's ear at a louder listening level. Although these devices can improve speech understanding in some patients, studies have shown that use of these devices does not ameliorate tinnitus or sound localization difficulties. Recent European studies have demonstrated that cochlear implantation (CI) can provide significant improvements in both perceived hearing ability and measured speech comprehension and localization in adult and pediatric patients with unilateral hearing loss. This suggests that CI may be a more effective option for this patient population than the CROS, BAHA or assistive devices.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cochlear Implantation for Treatment of Single-sided Deafness
Actual Study Start Date : September 2015
Actual Primary Completion Date : February 27, 2019
Actual Study Completion Date : April 25, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Cochlear Implant surgery
All subjects will be part of a single arm involving placement of the Med-El MAESTRO Cochlear Implant with Flex 28 electrode array
Device: Med-el MAESTRO Cochlear Implant with Flex 28 electrode array
Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
Other Names:
  • CI
  • cochlear implant

Primary Outcome Measures :
  1. Sound Detection Via Pure-tone Threshold Audiometry (PTA) [ Time Frame: 3, 6 and 12 months post-operatively ]
    Sound field thresholds following cochlear implantation via pure-tone threshold audiometry. Measured in dB HL (decibels hearing level) where a lower number means more sensitive hearing and a higher number means less sensitive hearing.

  2. Speech Perception Following Cochlear Implantation Assessed by Consonant-Nucleus-Consonant (CNC) Word Recognition Testing [ Time Frame: Preop, 1-4 weeks, and 3, 6, and 12 months post-operatively ]
    Ability to recognize words and sentences read by the tester from a set list at a loudness of 65 dB HL. The outcome is measured as a percent score of words recognized. The test takes place in a quiet environment.

Secondary Outcome Measures :
  1. Subjective Changes in Tinnitus Following Cochlear Implantation Measured by Tinnitus Handicap Index (THI) [ Time Frame: Preop and 12 months post-operatively ]
    Tinnitus severity rated by the Tinnitus Handicap Index (THI). The THI score of 0-16 means "no or slight handicap", 18 to 36 indicates "mild", 38 to 56 indicates "moderate", 58 to 76 indicates "severe", and a score of 78-100 is classified as "catastrophic handicap"

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older with the ability to provide informed consent
  • English as the primary language
  • Medically and psychologically suitable
  • Willing to receive/have received meningitis vaccinations
  • Able to pay for all care received through the study, either through the subject's insurance company or through self-pay
  • Able to comply with study requirements, including travel to the investigational sites
  • Severe to profound sensorineural hearing loss (≥70 dB HL (decibel hearing level) thresholds between 500 and 4000 Hz) in the worse ear with ≤ 20% Consonant-Nucleus-Consonant (CNC) word scores
  • Duration of single-sided deafness ≥ one year
  • Tinnitus localized to the affected ear, both ears, or in the head localized to the affected ear, both ears, or in the head

    • Expected subjects include those with:
  • Unilateral hearing loss secondary to viral or bacterial infection, such as meningitis or labyrinthitis
  • Ménière's disease
  • Sudden sensorineural hearing loss
  • Vascular disease affecting the inner ear
  • A combination of any number of the above conditions

Exclusion Criteria:

  • Duration of single-sided deafness ≥ ten years
  • Pure tone thresholds ≥ 35 dB HL at 500, 1000, 2000, and 4000 Hz in the better ear
  • Consonant-Nucleus-Consonant (CNC) word scores ≤ 70% in the better ear
  • Chronic otitis media in either ear
  • Inner ear malformation in either ear
  • Autoimmune inner ear disease (fluctuation sensorineural hearing loss in either ear)
  • Evidence of retrocochlear pathology, including vestibular schwannoma
  • Unilateral tinnitus in the unaffected ear
  • Cochlear ossification
  • Demonstrated cognitive and/or developmental challenges
  • Major depression or anxiety; post-traumatic stress disorder; substance abuse
  • Medical or psychological conditions that serve as contraindication to surgery
  • Additional handicaps that would prevent or limit participation in evaluations
  • Unrealistic patient or family expectations regarding the benefits, risks, and limitations inherent to the procedure and the prosthetic device
  • Pregnant women: The investigators will specifically ask all women of childbearing age if there is a possibility they are pregnant or trying to become pregnant at the initial clinic visit; any women who are pregnant or actively trying to become pregnant will be excluded. In cases that are questionable on the day of planned surgery, a pregnancy test will be performed as per current Massachusetts Eye & Ear Infirmary anesthesia pre-operative protocols.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02532972

Layout table for location information
United States, Massachusetts
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Dr. Daniel Lee
University of Wisconsin, Madison
Layout table for investigator information
Principal Investigator: Daniel J Lee, MD, FACS MEEI / MGH
  Study Documents (Full-Text)

Documents provided by Dr. Daniel Lee, Massachusetts Eye and Ear Infirmary:

Layout table for additonal information
Responsible Party: Dr. Daniel Lee, Director, Pediatric Otology and Neurotology, Massachusetts Eye and Ear Infirmary
ClinicalTrials.gov Identifier: NCT02532972    
Other Study ID Numbers: 13-054H
First Posted: August 26, 2015    Key Record Dates
Results First Posted: March 11, 2020
Last Update Posted: May 5, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Hearing Loss
Hearing Loss, Unilateral
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases